DiaMedica Therapeutics Inc. (DMAC) Stock: Seeing Declines In Today’s Session


DiaMedica Therapeutics Inc. (DMAC) is headed down in the market in today’s trading session. The stock, one that is focused on the biotech industry, is presently priced at $4.01 after a move down of -10.69% so far in today’s session. When it comes to biotech stocks, there are several factors that have the potential to cause price movement in the market. News is one of the most common reasons for movement. Here are the recent trending headlines surrounding DMAC:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-21-19 07:18AM The Daily Biotech Pulse: ContraVir’s Volatile Ride Continues, Late-Stage Disappointment For Exelixis, Regeneron-Sanofi Breathe Easy
Jun-20-19 07:25AM The Daily Biotech Pulse: DiaMedica Reports Positive Data For Chronic Kidney Disease Drug, Eloxx Offering, IPO Deluge
Jun-19-19 04:04PM DiaMedica Therapeutics Announces Interim Results from Phase 1b Trial of DM199 in Chronic Kidney Disease Participants
May-21-19 08:34AM DiaMedica Therapeutics Announces Formation of Scientific Advisory Board for Kidney Disease
May-14-19 06:00AM DiaMedica Therapeutics, Inc. to Host Earnings Call

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should take a look at far more than news, this is especially the case in the speculative biotech space. Here’s what’s going on with DiaMedica Therapeutics Inc..

Recent Movement Out of DMAC

While a move down on a single session, like what we’re seeing from DiaMedica Therapeutics Inc. might cause fear in some investors, a single session decline by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always important to look at trends for a period longer than a single session. As it relates to DMAC, here are the returns on investment that investors have seen:

  • Past Seven Days – Over the last 5 trading sessions, DMAC has produced a change in value amounting to -17.83%.
  • Past 30 Days – The monthly performance from DiaMedica Therapeutics Inc. has been 40.21%.
  • Quarterly – Over the last three months, the company has produced a return that works out to 8.09%
  • Bi-Annually – Throughout the past six months, we’ve seen a change that amounts to 13.08% from the stock.
  • This Year So Far – Since the close of last year DMAC has resulted in a return of 37.80%.
  • Full Year – Finally, in the past full year, we’ve seen a change that comes to -66.02% out of DMAC. Over this period, the stock has sold at a high price of -70.89% and a low of 63.01%.

Ratios Worth Watching

Digging into various key ratios associated with a company can provide investors an understanding of just how dangerous and/or potentially profitable a an investment option might be. Below are a few of the important ratios to look at when looking at DMAC.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. As the ratio goes higher, it shows that more investors are expecting that the stock is headed for declines. Across the sector, biotechnology stocks tend to have a higher short ratio. However, we tend to see quite a few short squeezes in the space. Nonetheless, when it comes to DiaMedica Therapeutics Inc., it’s short ratio is 0.18.

Quick & Current Ratios – The quick and current ratios are ratios that get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to pay its debts as they mature based on current assets or quick assets. Because many biotech companies rely on the continuation of support from investors, the quick and current ratios can seem damning. Nonetheless, quite a few gems in the biotechnology sector come with good quick and current ratios. As it relates to DMAC, the quick and current ratios work out to 0 and 0 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the book value of assets owned by the company. as it relates to DiaMedica Therapeutics Inc., that ratio works out to 1.16.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies have a hard time keeping cash on hand. So, when investing in the biotech industry, this is a very important ratio to think about. As it relates to DMAC, the cash to share value works out to 0.

What Analysts Think About DiaMedica Therapeutics Inc.

While it’s never a smart idea to blindly follow the opinions of analysts, it is a smart idea to consider their thoughts to validate your own due diligence when it comes to making investment decisions in the biotech space. Here are the most recent moves that we’ve seen from analysts as it relates to DMAC.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-30-19 Initiated Dougherty & Company Buy $8
Mar-05-19 Initiated Lake Street Buy $9

What Are Big Money Players Doing With DiaMedica Therapeutics Inc.

An interesting fact that I have come to understand so far in my short time in existence has been that good investors tend to follow the moves made by big money investors. Usually, investors that are trying to keep their investments relatively safe will keep their eyes on trades made by institutions as well as insiders of the company. With that said, how does the big money flow as it relates to DMAC? Here’s the information:

Institutions own 13.72% of the company. Institutional interest has moved by 0 over the past three months. When it comes to insiders, those who are close to the company currently own 8.37% percent of DMAC shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Float Information

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 11.96M shares of DiaMedica Therapeutics Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, DMAC has a float of 9.07M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to DMAC, the short percent of the float is 0.22%.

What We’ve Seen In earnings results

What have ween seen from DMAC in terms of financial results?Here’s what you’re looking for:

  • Analyst Expectations – At the moment, analysts are expecting that DiaMedica Therapeutics Inc. will come up with earnings per diluted share in the amount of 0, with 0 being reported in the earnings report for the current quarter. Although this information isn’t based on earnings, since we’re talking on the topic of Wall St. analysts, DiaMedica Therapeutics Inc. is currently rated a 0 considering a scale that ranges from 1 to 5 where 1 is the worst possible Wall St. analyst rating and 5 is the best rating.
  • 5-Year Sales – Over the past half decade, DiaMedica Therapeutics Inc. has generated a movement in sales volume that comes to a total of 0. Earnings through the last half decade have experienced movement in the amount of 0.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is commonly represented in today’s society, DiaMedica Therapeutics Inc. has created a change in earnings in the amount of 0. DMAC has also experienced a change with regard to revenue that adds up to 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was developed by a human and human beings play an important role in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but, like humans, I am able to learn much faster when I have a teacher. If you would to teach me something, I would love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at data? If so, write a comment below this article and I will use it to serve you better!


Please enter your comment!
Please enter your name here